Head-To-Head Review: Sangamo Therapeutics (NASDAQ:SGMO) & CERo Therapeutics (NASDAQ:CERO)

CERo Therapeutics (NASDAQ:CERO) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 15.8% of CERo Therapeutics shares are held by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares CERo Therapeutics and Sangamo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-23.86%
Sangamo Therapeutics	-1,749.06%	-182.55%	-110.56%

Analyst Ratings

This is a summary of recent ratings and target prices for CERo Therapeutics and Sangamo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0	0	0	0	N/A
Sangamo Therapeutics	0	3	3	0	2.50

Sangamo Therapeutics has a consensus price target of $5.67, indicating a potential upside of 550.44%. Given Sangamo Therapeutics’ higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than CERo Therapeutics.

Risk and Volatility

CERo Therapeutics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares CERo Therapeutics and Sangamo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A
Sangamo Therapeutics	$18.76 million	9.64	-$257.83 million	($1.86)	-0.47

CERo Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.